Literature DB >> 24676297

Bariatric surgery reverses metabolic risk in patients treated in outpatient level.

Epifânio Feitosa da Silva-Neto1, Cecília Ma Passos Vázquez1, Fabiana Melo Soares1, Danielle Góes da Silva1, Márcia Ferreira Cândido de Souza1, Kiriaque Barra Ferreira Barbosa1.   

Abstract

BACKGROUND: The conventional treatment of obesity presents unsatisfactory results on weight loss and its long-term sustainability, therefore bariatric surgery has been suggested as an effective therapy, determining sustainable long-term weight loss, reversal of components of cardiometabolic risk and improved quality and life expectancy. AIM: To investigate the clinical component of the cardiometabolic risk in patients undergoing bariatric surgery assisted on outpatient basis. Methods : The sample consisted of 47 patients with ages between 18 and 60 years, 72% females. Diabetes mellitus, hypertension, and dyslipidemia were prospectively evaluated by using the Assessment of Obesity-Related Co-morbidities scale.
RESULTS: Occurred improvement in these co-morbidities within 12 months after surgery. Co-morbidities resolved were greater than those improved.
CONCLUSION: The study revealed that the Assessment of Obesity-Related Co-morbidities is a system that can be effectively used to quantify the degree of reduction of the severity of the cardiometabolic risk in response to bariatric surgery.

Entities:  

Mesh:

Year:  2014        PMID: 24676297      PMCID: PMC4675484          DOI: 10.1590/s0102-67202014000100010

Source DB:  PubMed          Journal:  Arq Bras Cir Dig        ISSN: 0102-6720


INTRODUCTION

Obesity and its co-morbidities have reached alarming prevalence, becoming a public health problem worldwide, independent of gender, age and social status. From the unsatisfying results seen in conventional treatment on weight loss and its long term sustainability, bariatric surgery has been pointed out as an efficient treatment, determining sustainable weight loss, cardiometabolic risk factors (CMR) and life expectancy and quality improvements[7,8,12]. Weight loss and maintenance after bariatric surgery can be understood by behavior changes that are inserted in the patient's life. The food habit change provided by the adoption of a high calorie diet associated to ingestion of high nutritional value foods and the beginning of a regular physical activity, are essential measurements that help the weight loss after surgery. Besides behavior factors, the Roux Y gastric by-pass surgery technique contributes, through anatomy and hormonal changes, in a significant manner, to loss and maintenance of weight with the best co-morbidities[1,12,14]. Individuals submitted to bariatric surgery with nutritional assistance can achieve loss of 40 to 50% from the initial weight in a short period of time, being possible the long term maintenance[2]. The favorable effect of the gastric pouch reduction and the jejunal derivation in Roux Y considering reversion and control of the CMR components is described in many populations [10,5,9,3]. Mohamed et al (2009)[11] proposed an instrument capable of measuring, in a quantitative manner, the co-morbidities changes related to obesity after bariatric surgery, with this instrument it is possible to quantify the enhancement of revise the components of cardio metabolic risk. Life expectation increase and mortality reduction with surgery is, partly, mediated by CMR reversion; therefore, the present study has as goal to evaluate and quantify the clinical evolution of CMR components in patients submitted to bariatric surgery by Roux Y laparoscopic method, assisted in ambulatory level.

METHODS

The study is transversal, with sampling by convenience, carried out at the nutrition ambulatory of the Universidade Federal de Sergipe (CAAE nº 0281.0.107.000-11). Data collection was taken from records and protocols, using ambulatory assistance for the patients, in a period from May to June of 2012, 47 records of patients submitted to bariatric surgery, were selected. The records that were included in the study were properly filled, presenting all data, with diagnose at the admission of the following co-morbidities associated to obesity: arterial hypertension, dyslipidemia and diabetes mellitus. Anthropometric data referring to weight and height were checked by recommended techniques and instruments, the Body Mass Index (BMI) was calculated and the nutritional state classified, according to cutting points of the World Health Organization[6]. Biochemical and clinical data related to serum and plasmatic doses of triglycerides, total cholesterol, cholesterol - HDL, cholesterol - LDL and jejunal glucose, were collected. Further systolic and diastolic arterial pressure were measured. Clinical evaluation of the cardiometabolic risk components ( CMR) evolution was quantified, according to a proposal presented in previous study, taking scores calculus related to Obesity-Related Co-Morbidities Evaluation (ORCE). It was based in a points system which attributed scores from 0 - 5, according to severity for CMR components: diabetes mellitus , dyslipidemia and systemic arterial hypertension (Figure 1). The scores were attributed to the admission time, surgery authorization and after surgery return, on the 3rd, 6th and 12th month, approximately.
FIGURE 1

Assessment of Obesity-Related Co-morbidities (AORC)

AORC scoreDescription
Diabetes mellitus  
0Absence
1Glucose Intolerance
2Diabetes mellitus (diagnosed)
3Controlled with an oral anti-diabetic
4Insulin therapy
5Clinical Complications
Dyslipidemia  
0Absence
1Limit values (200-239 mg/dl)
2Conventional control (diet + physical activity)
3Single medication
4Multiple medication
5Non-controlled
Hypertension  
0Absence
1Limit values (systolic: 130- 139 mmHg; dyastolic:85-89 mmHg)
2Conventional control (diet + physical activity)
3Single medication
4Multiple medication
5Non-controlled
Assessment of Obesity-Related Co-morbidities (AORC)

Statistical analysis

The medium (X), standard deviation (SD), absolute (n) and relative (%) frequency, were calculated. Due to sample size and variables distribution, non-parametric tests were adopted. The W-Wilcoxon test was used to compare different moments of nutritional assistance. For categorical variables the Qui-Square test was used. A 5% probability statistical significance (p<0.05) was considered. Statistical analysis were carried out using the Statistical Package for the Social Science (SPSS), version 17.0 for Windows.

RESULTS

Forty-seven patients participated on this study, being 72% women (44 y). At admission the prevalence of obesity grade III was 100%; at surgery and 12 months after, a percentage reduction was seen, for 80,9% and 34.2%, respectively (Table 1).
TABLE 1

Patients characterization in bariatric surgery pre and post-operation in ambulatory assistance

 n%
Gender  
Women3472,0
Age (years)  
    20-391836,0
    40-592757,0
    ≥ 6024,0
Nutritional state at admission  
    Eutrophic00,0
    Over weight00,0
    Obesity grade I00,0
    Obesity grade II00,0
    Obesity grade III47100,0
Nutritional state at surgery  
    Eutrophic00,0
    Over weight00,0
    Obesity grade I12,1
    Obesity grade II817,0
    Obesity grade III3880,9
Nutritional state post-operation  
    Eutrophic12,6
    Over weight37,9
    Obesity grade I1128,9
    Obesity grade II1026,3
    Obesity grade IIIa1334,2
 χDP
Age43,6±9,8
Admission age141,5±27,0
Surgery Age132,6±27,0
Post– operation agea101,9±23,3
Admission BMI53,5±8,8
Surgery BMI50,1±9,2
Post–operation BMIa38,6±8,2
Nutritional assistance time (years)a2,6±2,0
Pre-operation time (years)1,7±1,8
Post–operation time (years)a0,8±0,7

BMI: Body mass index; n: absolute frequency, %: relative frequency, χ: medium; SD: standard deviation; a Sample Loss, n=38

Patients characterization in bariatric surgery pre and post-operation in ambulatory assistance BMI: Body mass index; n: absolute frequency, %: relative frequency, χ: medium; SD: standard deviation; a Sample Loss, n=38 Table 2, shows a significant reduction on average score of all co-morbidities related to obesity, CMR components, since admission up to 12 months after. The average score was, sensibly, higher for arterial hypertension, showing at admission a total of 80.9% patients in medication treatment or presenting complication, showing a considerable reduction at 3, 6 and 12 months post-operation. These findings were also expressed for the remaining CMR, dyslipidemia and diabetes mellitus type 2 components.
TABLE 2

Co-morbidities assessment scores related to obesity (AORC), according to different nutritional assistance moments

AORC scoreAdmissionSurgeryPO3PO6PO12
Diabetes mellitus     
    Average score0,8±1,30,6±1,2*0±0**0±0**0±0**
    ≤ 237 (78,7)38 (80,9)47 (100)43(100)[a]37(100)[b]
    ≥ 310 (21,3)9 (19,1)000
Dyslipidemia     
    Average score2,1±1,61,8±1,6*0,1±0,4**0±0**0±0**
    ≤ 218 (38,3)20 (42,6)46 (97,9)43 (100)[a]37 (100)[b]
    ≥ 329 (61,7)27 (57,4)1 (2,1)0[a]0[b]
Hypertension     
    Average score3±1,42,6±1,3*0,4±0,9**0,1±0,4**0,1±0,5**
    ≤ 29 (19,1)9 (19,1)42 (89,4)42 (97,7)[a]36 (97,3)[b]
    ≥ 338 (80,9)38 (80,9)4 (8,5)1 (2,3)[a]1 (2,7)[b]
Cardio metabolic risks8 (17)8 (17)00[a]0[b]

AORC score ≤2: patients in non-medication treatment; AORC score ≥3: patients in medication treatment or presenting complications; cardiometabolic risks: AORC score ≥3 for all three co-morbidities: diabetes mellitus, dyslipidemia and hypertension; PO3: post-operation at three months, nearly; PO6: post-operation at six months, nearly; PO12: post-operation at 12 months, nearly. Average data and standard deviation [χ±SD] or absolute and relative frequency [n (%)]. a,b Sample loss,

n=43,

n=37;

p<0,05; W Wilcoxon surgery test relating to admission;

p<0,05; W Wilcoxon surgery test relating to post-operation.

Co-morbidities assessment scores related to obesity (AORC), according to different nutritional assistance moments AORC score ≤2: patients in non-medication treatment; AORC score ≥3: patients in medication treatment or presenting complications; cardiometabolic risks: AORC score ≥3 for all three co-morbidities: diabetes mellitus, dyslipidemia and hypertension; PO3: post-operation at three months, nearly; PO6: post-operation at six months, nearly; PO12: post-operation at 12 months, nearly. Average data and standard deviation [χ±SD] or absolute and relative frequency [n (%)]. a,b Sample loss, n=43, n=37; p<0,05; W Wilcoxon surgery test relating to admission; p<0,05; W Wilcoxon surgery test relating to post-operation. Table 3 shows the clinical evolution of the CMR components during nutritional assistance pre and post-operation and total. It was possible to evaluate that all co-morbidities evaluated, independent of nutritional assistance at the moment, the patients amount, that had them reverted overcame the one that had them just enhanced. Related to reverted co-morbidities, except one case of dyslipidemia, reverted still in pre-operatory, all were reverted in post-operation or total assistance. It is important to note that the higher the level of complications the longer it took for reversing the pathology, once that the patients that evolved from score 3 to 0 was higher in post-operation nutritional assistance, while that evolved from score 4 to 0, made necessary a higher intervention time, being the evolution, predominantly, in total assistance, therefore, since admission, involving pre and post-operation assistance. The reversion since the moment of highest complication, of the score from 5 to 0, was possible only for one diabetes mellitus case. The treatment medication abolition for mellitus diabetes and dislipidemia, was possible still at pre-operation in 2.1% and 4.2% of the cases respectively.
TABLE 3

Cardiometabolic risk component evolution in patients submitted to bariatric surgery, according to different nutritional assistance

Score evolution AORCDiabetesDyslipidemiaArterial hipertension
 
Reverse co-morbidity         
3 → 008(17,4)[a]7(15,2)[a]1(2,1)22 (47,8)[a]16 (36,4)[b]027 (62,8)[c]14 (29,8)
4 → 000002(4,4)[d]10(21,3)06(12,8)19(44,2)[c]
5 → 0001(2,1)000000
Enhanced co-morbidity         
3 → 11(2,1)0[a]0[a]1(2,1)0[a]0[b]00[c]0
3 → 200[a]0[a]00[a]0[b]00[c]0
4 → 10000[d]00000[c]
4 → 200000[d]0000[c]
4 → 30009(19,1)0[d]020(42,6)01(2,3)[c]
5 → 1000000000
5 → 2000000000
5 → 31(2,1)00000000
5 → 4000000000
Medication treatment reversed1(2,1)8(17,4)8(17,3)2(4,2)24(43,4)26(57,7)033(75,6)33(74)
No medication00070001332

1º Pre-operation nutritional assistance; 2º Post-operation nutritional assistance; 3º Total nutritional assistance; Relative and absolute frequency presented in data [n (%)]

a, b, c, d Sample loss,

n=46 an=46,

n=44,

n=43,

n=45

Cardiometabolic risk component evolution in patients submitted to bariatric surgery, according to different nutritional assistance 1º Pre-operation nutritional assistance; 2º Post-operation nutritional assistance; 3º Total nutritional assistance; Relative and absolute frequency presented in data [n (%)] a, b, c, d Sample loss, n=46 an=46, n=44, n=43, n=45

DISCUSSION

In studies carried out in Brazil with bariatric patients, it was not still evidenced a method and/or instrument that can quantify the benefits of the surgery for the health of these patients. The AORC consists of a standardized and easy use method, proposing the evaluation of patients submitted to bariatric surgery, because the use of this instrument expresses in a quantitative form the clinical evaluation of the surgical treatment of obesity[11]. On most studies, the co-morbidities control is presented in a qualitative form. In the present study the control referred was quantified, as proposed by Mohamed et al (2009)[11]. After applying AORC a clinical evolution was observed marked by the significant reduction of average score of co-morbidities related to obesity (diabetes mellitus, arterial hypertension, dislipidemia), from the obesity surgical treatment, as of the pre-operation conventional treatment. A higher nutritional assistance time before bariatric surgery, can contribute for co-morbidities control associated to disease, mainly, arterial hypertension, through the adoption of a new food habit and regular physical activity practice, being the patient capable of presenting, still in a pre-surgical period, important clinical enhancements associated to CMR[6]. Previous studies show enhancement in several clinical manifestations of CMR being controlled or reduced in almost totality[3,5,9,10]. However, especially in case of diabetes, this enhancement can be attributed to weight loss and better resistance to insulin, since, the evolution of the same is observed almost immediately after surgical procedure[12]. Besides gastric reduction and duodenal derivation that directly help weight loss, enhancement or reversion of diabetes type 2, after surgery is due, mainly, for anatomic and hormonal alterations from the gastrojejunal derivation. Due to anatomic approximation between the stomach and the ileum, the food will reach the distal intestine earlier and, as consequence, a higher production of incretin GLP - 1 and GIP, besides the production of ghrelin. Once they are liberated, the incretin act in the pancreas stimulating the production of insulin that will contribute with the glycemic control[1,10,12,14]. The ghrelin production reduction is provoked by the gastric end exclusion characterizing the sacietogen effect of this surgery[4,12]. The reduction, or even the abolition of medication, after surgery treatment, as evidenced in this study is a condition, probably influenced by the long term sustainable weight loss, food habits improvement and regular physical activity practice, determined by surgery treatment of obesity, reflecting not only in socio-economical life of the patients, but, mainly, enhancing the life quality of these individuals[4]. By AOCR it was possible to evidence the clinical evolution of the patients submitted to surgery treatment of obesity in our institution.

CONCLUSION

The Assessment of Obesity-Related Co-morbidities is a system that can be effectively used to quantify the degree of reduction of the severity of the cardiometabolic risk in response to bariatric surgery.
  12 in total

1.  Evaluation of quality of life in severely obese patients after bariatric surgery carried out in the public healthcare system.

Authors:  Cristina Khawali; Marcos Bosi Ferraz; Maria Tereza Zanella; Sandra R G Ferreira
Journal:  Arq Bras Endocrinol Metabol       Date:  2012-02

Review 2.  The metabolic syndrome: time to get off the merry-go-round?

Authors:  G M Reaven
Journal:  J Intern Med       Date:  2010-12-03       Impact factor: 8.989

Review 3.  Weight recidivism post-bariatric surgery: a systematic review.

Authors:  Shahzeer Karmali; Balpreet Brar; Xinzhe Shi; Arya M Sharma; Christopher de Gara; Daniel W Birch
Journal:  Obes Surg       Date:  2013-11       Impact factor: 4.129

4.  Current nutritional treatments of obesity.

Authors:  Ashli Greenwald
Journal:  Adv Psychosom Med       Date:  2006

Review 5.  Quality of life of diabetic patients with medical or surgical treatment.

Authors:  S Weiner; E A M Neugehauer
Journal:  Nutr Hosp       Date:  2013-03       Impact factor: 1.057

Review 6.  [Does bariatric surgery cure the metabolic syndrome?].

Authors:  Bruno Geloneze; José Carlos Pareja
Journal:  Arq Bras Endocrinol Metabol       Date:  2006-05-23

7.  Metabolic syndrome: yet another co-morbidity gastric bypass helps cure.

Authors:  Atul K Madan; Whitney Orth; Craig A Ternovits; David S Tichansky
Journal:  Surg Obes Relat Dis       Date:  2006 Jan-Feb       Impact factor: 4.734

8.  [Can bariatric surgery cure metabolic syndrome?].

Authors:  Perseu Seixas de Carvalho; Cora Lavigne de C B Moreira; Melina da Costa Barelli; Flávia Heringer de Oliveira; Mariana Furieri Guzzo; Gustavo P Soares Miguel; Eliana Zandonade
Journal:  Arq Bras Endocrinol Metabol       Date:  2007-02

9.  Effects of laparoscopic sleeve gastrectomy in patients with morbid obesity and metabolic disorders.

Authors:  Jacopo Desiderio; Stefano Trastulli; Vittorio Scalercio; Eva Mirri; Ilenia Grandone; Roberto Cirocchi; Jacopo Penzo; Alberto Santoro; Adriano Redler; Carlo Boselli; Giuseppe Noya; Giuseppe Fatati; Amilcare Parisi
Journal:  Diabetes Technol Ther       Date:  2013-08-28       Impact factor: 6.118

10.  Effects of laparoscopic gastric banding on body composition, metabolic profile and nutritional status of obese women: 12-months follow-up.

Authors:  V Giusti; M Suter; E Héraïef; R C Gaillard; P Burckhardt
Journal:  Obes Surg       Date:  2004-02       Impact factor: 4.129

View more
  4 in total

1.  Assessment of Cardiometabolic Risk Factors, Physical Activity Levels, and Quality of Life in Stratified Groups up to 10 Years after Bariatric Surgery.

Authors:  Larissa Monteiro Costa Pereira; Felipe J Aidar; Dihogo Gama de Matos; Jader Pereira de Farias Neto; Raphael Fabrício de Souza; Antônio Carlos Sobral Sousa; Rebeca Rocha de Almeida; Marco Antonio Prado Nunes; Albená Nunes-Silva; Walderi Monteiro da Silva Júnior
Journal:  Int J Environ Res Public Health       Date:  2019-06-04       Impact factor: 3.390

2.  IMMUNOLOGICAL EVALUATION OF PATIENTS WITH TYPE 2 DIABETES MELLITUS SUBMITTED TO METABOLIC SURGERY.

Authors:  Marisa de Carvalho Borges; Guilherme Azevedo Terra; Tharsus Dias Takeuti; Betânia Maria Ribeiro; Alex Augusto Silva; Júverson Alves Terra-Júnior; Virmondes Rodrigues-Júnior; Eduardo Crema
Journal:  Arq Bras Cir Dig       Date:  2015 Nov-Dec

3.  EFFECTS OF LONG-TERM ROUX-EN-Y GASTRIC BYPASS ON BODY WEIGHT AND CLINICAL METABOLIC COMORBIDITIES IN BARIATRIC SURGERY SERVICE OF A UNIVERSITY HOSPITAL.

Authors:  Cátia Ferreira da Silva; Larissa Cohen; Luciana d'Abreu Sarmento; Felipe Monnerat Marino Rosa; Eliane Lopes Rosado; João Régis Ivar Carneiro; Antônio Augusto Peixoto de Souza; Fernanda Cristina Carvalho Mattos Magno
Journal:  Arq Bras Cir Dig       Date:  2016

4.  A Retrospective Study about the Differences in Cardiometabolic Risk Indicators and Level of Physical Activity in Bariatric Surgery Patients from Private vs. Public Units.

Authors:  Rebeca Rocha de Almeida; Márcia Ferreira Cândido de Souza; Dihogo Gama de Matos; Larissa Monteiro Costa Pereira; Victor Batista Oliveira; Joselina Luzia Menezes Oliveira; José Augusto Soares Barreto-Filho; Marcos Antonio Almeida-Santos; Raphael Fabrício de Souza; Aristela de Freitas Zanona; Victor Machado Reis; Felipe J Aidar; Antônio Carlos Sobral Sousa
Journal:  Int J Environ Res Public Health       Date:  2019-11-27       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.